Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 22, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

March 1, 2029

Conditions

Anaplastic Throid Carcinoma

Interventions

DRUG

NKG2D CAR-NK with PD-1 Antibody

Treated with CAR-NK immune cells combined with PD-1 monoclonal antibody.

Trial Locations (1)

Zhejiang Provincial People's Hospital, Hangzhou

All Listed Sponsors

lead

Zhejiang Provincial People's Hospital

OTHER

NCT06856278 - Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC | Biotech Hunter | Biotech Hunter